The OncFive: Top Oncology Articles for the Week of 5/4
A doublet is approved for KRAS-mutated ovarian cancer, T-DXd followed by THP improves pCR rates in HER2+ breast cancer, and more from OncLive.
Related Articles
Large Clonal Hematopoiesis Clones Are Associated With Worse Survival Outcomes in MCL
Patients with MCL and large clonal hematopoiesis clones experienced shortened PFS and OS vs those without clones.
CX-2051 Demonstrates Preliminary Activity in Heavily Pretreated Advanced Colorectal Cancer
CX-2051 elicited an overall response rate of 28% with manageable safety in heavily pretreated colorectal cancer.
Avutometinib/Defactinib Expands Treatment Options for KRAS-Mutant Low-Grade Serous Ovarian Cancer
Bradley Monk, MD, FACOG, FACS, discusses the FDA approval of avutometinib plus defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer.
Five Under 5: Top Oncology Videos for the Week of 5/4
The top 5 OncLive videos of the week cover insights in myelodysplastic syndrome, lung cancer, hepatocellular carcinoma, colorectal cancer, and ovarian cancer.
Nadofaragene Firadenovec Yields High 3-Month CR Rates in High-Risk BCG-Unresponsive NMIBC With CIS
Nadofaragene firadenovec was safe and produced high CR rates at 3 months in Japanese patients with high-risk BCG-unresponsive NMIBC and CIS.
Oncodetect Test Is Now Available for MRD Detection in Solid Tumors
The Oncodetect test is now available for use in molecular residual disease detection in patients with solid tumors.
Salvage ASCT Shows No Long-Term PFS or OS Benefit in Relapsed Myeloma
Salvage transplant was not associated with long-term survival benefits in relapsed/refractory multiple myeloma.
Sacituzumab Govitecan Plus Pembrolizumab Improves PFS in PD-L1–Positive mTNBC
The combination of sacituzumab govitecan and pembrolizumab improved PFS vs pembrolizumab plus chemotherapy in PD-L1–positive mTNBC.
T-DXd/Pertuzumab Yields PFS Benefit vs THP in HER2+ Metastatic Breast Cancer
Frontline T-DXd plus pertuzumab led to statistically significant and clinically meaningful PFS improvements vs THP in HER2+ metastatic breast cancer.
Treatment Strategies in 2L R/R FL: When to Treat vs Observe in Relapsed Disease
Panelists discuss how the treatment approach for relapsed or progressive follicular lymphoma (R/R FL) in the second-line (2L) setting is evolving, focusing on the role…